Suppr超能文献

在个性化医疗时代规避癌症药物耐药性。

Circumventing cancer drug resistance in the era of personalized medicine.

机构信息

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

出版信息

Cancer Discov. 2012 Mar;2(3):214-26. doi: 10.1158/2159-8290.CD-12-0012. Epub 2012 Feb 28.

Abstract

UNLABELLED

All successful cancer therapies are limited by the development of drug resistance. The increase in the understanding of the molecular and biochemical bases of drug efficacy has also facilitated studies elucidating the mechanism(s) of drug resistance. Experimental approaches that can help predict the eventual clinical drug resistance, coupled with the evolution of systematic genomic and proteomic technologies, are rapidly identifying novel resistance mechanisms. In this review, we provide a historical background on drug resistance and a framework for understanding the common ways by which cancers develop resistance to targeted therapies. We further discuss advantages and disadvantages of experimental strategies that can be used to identify drug resistance mechanism(s).

SIGNIFICANCE

Increased knowledge of drug resistance mechanisms will aid in the development of effective therapies for patients with cancer. We provide a summary of current knowledge on drug resistance mechanisms and experimental strategies to identify and study additional drug resistance pathways.

摘要

非标记

所有成功的癌症治疗都受到耐药性发展的限制。对药物疗效的分子和生化基础的理解增加,也促进了阐明耐药机制的研究。有助于预测最终临床耐药性的实验方法,加上系统基因组和蛋白质组学技术的发展,正在迅速确定新的耐药机制。在这篇综述中,我们提供了耐药性的历史背景,并提供了一个理解癌症对靶向治疗产生耐药性的常见方式的框架。我们进一步讨论了可用于确定耐药机制的实验策略的优缺点。

意义

增加对耐药机制的认识将有助于为癌症患者开发有效的治疗方法。我们提供了对耐药机制和实验策略的当前知识的总结,以识别和研究其他耐药途径。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验